Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
29 hedge funds and large institutions have $11.5M invested in Carisma Therapeutics in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 6 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
38% more capital invested
Capital invested by funds: $8.34M → $11.5M (+$3.2M)
16% more funds holding
Funds holding: 25 → 29 (+4)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $93K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$854K |
| 2 |
Millennium Management
New York
|
+$294K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$242K |
| 4 |
DTL
Dynamic Technology Lab
Singapore
|
+$154K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$931K |
| 2 |
Renaissance Technologies
New York
|
-$198K |
| 3 |
Bank of New York Mellon
New York
|
-$100K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$42K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$25K |
CARM Hedge Fund Activity: Q3 2016 in Review
29 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2016, worth a combined $11.5M — up 38% from $8.34M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CARM positions and 6 closed out — a net gain of 6 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock Institutional Trust, adding an estimated $854K. The largest seller was Boxer Capital, cutting an estimated $931K.
- 29 institutional investors held Carisma Therapeutics (CARM) as of Q3 2016, up from 25 in Q2 2016.
- Funds reported $11.5M of Carisma Therapeutics stock for Q3 2016, up 38% quarter-over-quarter.
- 12 funds opened new Carisma Therapeutics positions in Q3 2016 and 6 closed out, a net change of +6 holders.
- The largest Carisma Therapeutics buyer in Q3 2016 was BlackRock Institutional Trust, an estimated $854K added.
- The largest Carisma Therapeutics seller in Q3 2016 was Boxer Capital, an estimated $931K sold.
Based on aggregated 13F filings for Q3 2016.